Table 3.
The possible dependence between the clinical benefit of WPRT and patient characteristics in RCTs.
| Heterogeneity factors | RCT | No. of events/Total no.WPRT PORT | Hazard ratio (95% CI) WPRT vs. PORT | p-Value | |
|---|---|---|---|---|---|
| Age years for BFFS | POP-RT | ||||
| ≤66 | 2/59 | 22/58 | 0.08 [0.02, 0.35] | 0.03 | |
| >66 | 5/51 | 7/54 | 0.66 [0.21, 2.10] | ||
| Gleason for BFFS | POP-RT | ||||
| <8 | 2/57 | 9/56 | 0.22 [0.05, 1.01] | 0.88 | |
| ≥8 | 5/53 | 20/56 | 0.24 [0.09, 0.64] | ||
| Nodal Risk for BFFS | POP-RT | ||||
| ≤40% | 4/59 | 11/60 | 0.36 [0.12, 1.14] | 0.28 | |
| <40% | 3/51 | 18/52 | 0.15 [0.04, 0.50] | ||
| Gleason for PFS | GETUG 12 | ||||
| <8 | 52/111 | 27/89 | 1.26 [0.76, 2.09] | 0.20 | |
| ≥8 | 53/97 | 30/61 | 0.95 [0.59, 1.53] | ||
| Age years for DMFS | POP-RT | ||||
| ≤66 | 2/59 | 17/58 | 0.11[0.03, 0.49] | 0.01 | |
| >66 | 5/51 | 3/54 | 1.63[0.39, 6.85] | ||
| Gleason for DMFS | POP-RT | ||||
| <8 | 2/57 | 6/56 | 0.32[0.06, 1.60] | 0.88 | |
| ≥8 | 5/53 | 14/56 | 0.37[0.13, 1.04] | ||
WPRT, whole-pelvic radiotherapy; PORT, prostate-only radiotherapy; RCT, randomized controlled trial; BFFS, biochemical failure-free survival; PFS, progression-free survival; DMFS, distant metastasis-free survival.